CYTOF — Altamira Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.52m
- $1.31m
Annual income statement for Altamira Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.63 | 7.52 | 18.9 | 6.58 | 6.85 |
| Operating Profit | -5.63 | -7.52 | -18.9 | -6.58 | -6.85 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.76 | -7.45 | -19.5 | -8.09 | -8.46 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.74 | -7.32 | -19.5 | -8.09 | -8.46 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -8.74 | -18.7 | -27.8 | -4.31 | -8.46 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.74 | -18.7 | -27.8 | -4.31 | -8.46 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -581 | -188 | -244 | -16.5 | -2.99 |